Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genaissance Pharmaceuticals (GNSC) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (10)	11/27/2000 12:54:31 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 183

Genaissance Pharmaceuticals Inc. (GNSC) signed a multi-year agreement with Johnson & Johnson's (JNJ) Janssen Research Foundation for discovery, development and commercial applications of Genaissance's HAP genetic database. Financial terms weren't disclosed. In a press release Monday, Genaissance said the Janssen Research Foundation and the R.W. Johnson Pharmaceutical Research Institute will install the Genaissance HAP Technology platform under a license granted by Genaissance. The HAP Technology includes the Isogenomics database of HAP markers for pharmaceutically relevant genes and the proprietary DecoGen Informatics system, which provides data management and genetic analysis capabilities, including correlation of HAP Markers and drug response. Genaissance Pharmaceuticals is a genomic research company applying population genomics and clinical data to the development of medicine.